Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology
The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edem...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | International Journal of Cell Biology |
Online Access: | http://dx.doi.org/10.1155/2012/176287 |
id |
doaj-03f0bbd2593940a3b2dd7c37e8050406 |
---|---|
record_format |
Article |
spelling |
doaj-03f0bbd2593940a3b2dd7c37e80504062020-11-24T23:37:01ZengHindawi LimitedInternational Journal of Cell Biology1687-88761687-88842012-01-01201210.1155/2012/176287176287Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic PathophysiologyVincent Berezowski0Andrew M. Fukuda1Roméo Cecchelli2Jérôme Badaut3Université Lille Nord de France, 59000 Lille, FranceDepartments of Physiology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USAUniversité Lille Nord de France, 59000 Lille, FranceDepartments of Physiology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USAThe neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke.http://dx.doi.org/10.1155/2012/176287 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vincent Berezowski Andrew M. Fukuda Roméo Cecchelli Jérôme Badaut |
spellingShingle |
Vincent Berezowski Andrew M. Fukuda Roméo Cecchelli Jérôme Badaut Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology International Journal of Cell Biology |
author_facet |
Vincent Berezowski Andrew M. Fukuda Roméo Cecchelli Jérôme Badaut |
author_sort |
Vincent Berezowski |
title |
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology |
title_short |
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology |
title_full |
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology |
title_fullStr |
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology |
title_full_unstemmed |
Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology |
title_sort |
endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology |
publisher |
Hindawi Limited |
series |
International Journal of Cell Biology |
issn |
1687-8876 1687-8884 |
publishDate |
2012-01-01 |
description |
The neurovascular/gliovascular unit has recently gained increased attention in cerebral ischemic research, especially regarding the cellular and molecular changes that occur in astrocytes and endothelial cells. In this paper we summarize the recent knowledge of these changes in association with edema formation, interactions with the basal lamina, and blood-brain barrier dysfunctions. We also review the involvement of astrocytes and endothelial cells with recombinant tissue plasminogen activator, which is the only FDA-approved thrombolytic drug after stroke. However, it has a narrow therapeutic time window and serious clinical side effects. Lastly, we provide alternative therapeutic targets for future ischemia drug developments such as peroxisome proliferator- activated receptors and inhibitors of the c-Jun N-terminal kinase pathway. Targeting the neurovascular unit to protect the blood-brain barrier instead of a classical neuron-centric approach in the development of neuroprotective drugs may result in improved clinical outcomes after stroke. |
url |
http://dx.doi.org/10.1155/2012/176287 |
work_keys_str_mv |
AT vincentberezowski endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology AT andrewmfukuda endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology AT romeocecchelli endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology AT jeromebadaut endothelialcellsandastrocytesaconcertoenduoinischemicpathophysiology |
_version_ |
1725521316524589056 |